Positron Corporation

Life Molecular Imaging announces an ongoing collaboration with UCB for PI-2620, a novel tau imaging agent, for improved diagnosis of Progressive Supranuclear Palsy

Retrieved on: 
Wednesday, March 3, 2021
Medicine, Nuclear medicine, Clinical medicine, Neuroimaging, Medical imaging, Medicinal radiochemistry, Radiopharmaceuticals, Positron emission tomography, Molecular imaging, Progressive supranuclear palsy, Positron Corporation, PET radiotracer

BERLIN, March 3, 2021 /PRNewswire-PRWeb/ --Life Molecular Imaging today announces an ongoing collaboration with UCB Biopharma to investigate the utility of the tau-positron emission tomography (PET) tracer PI-2620 in patients with progressive supranuclear palsy (PSP).

Key Points: 
  • BERLIN, March 3, 2021 /PRNewswire-PRWeb/ --Life Molecular Imaging today announces an ongoing collaboration with UCB Biopharma to investigate the utility of the tau-positron emission tomography (PET) tracer PI-2620 in patients with progressive supranuclear palsy (PSP).
  • PI-2620 was discovered and developed in a research collaboration between Life Molecular Imaging and AC Immune, a Swiss-based clinical stage biopharmaceutical company [2].
  • Life Molecular Imaging has the exclusive, worldwide license for research, clinical development and commercialization of tau PET tracers generated within the discovery program.
  • Chotipanich et al., "Evaluation of Imaging Windows for Tau PET Imaging Using 18F-PI-2620 in Cognitively Normal Individuals, Mild Cognitive Impairment, and Alzheimer's Disease Patients" Molecular Imaging.

Fuzionaire Radioisotope Technologies K.K. and Nihon Medi-Physics Enter Feasibility Study Agreement

Retrieved on: 
Tuesday, January 26, 2021
Health, Medical devices, Radiology, Research, Science, Pharmaceutical, Biotechnology, Medicine, Physical sciences, Medicinal radiochemistry, Nuclear medicine, Medical physics, Radiopharmaceuticals, Neuroimaging, Radioactivity, Positron Corporation, Positron emission tomography, Positron emission

(FRIT) today announced that it has entered into a feasibility study agreement with Nihon Medi-Physics Co., Ltd. (NMP), a leading radiopharmaceutical company in Japan, engaged in R&D, manufacturing, and distribution.

Key Points: 
  • (FRIT) today announced that it has entered into a feasibility study agreement with Nihon Medi-Physics Co., Ltd. (NMP), a leading radiopharmaceutical company in Japan, engaged in R&D, manufacturing, and distribution.
  • Founded in 2019, FRIT is a joint venture between radiopharmaceutical companies Fuzionaire Diagnostics, Inc. (Fuzionaire Dx) and Japan Medical Isotope Technology Development K.K.
  • Under the agreement, NMP will evaluate the ability of Fuzionaire Dxs technology to create a new class of positron emission tomography (PET) radiopharmaceuticals.
  • Fuzionaire Diagnostics (Fuzionaire Dx) is a nuclear medicine company on a mission to improve disease, diagnosis, and treatment.

Insights on the Medical Imaging Information Systems Global Market to 2027 - Featuring Esaote, Fujifilm and GE Healthcare Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 20, 2021
Medical devices, Health, Medicine, Nuclear medicine, Medical physics, Positron Corporation, Medical imaging, Tomography, Positron emission tomography

The "Medical Imaging Information Systems - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Medical Imaging Information Systems - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • The 294-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021.
  • The U.S. Market is Estimated at $221.6 Million, While China is Forecast to Grow at 6.7% CAGR
    The Medical Imaging Information Systems market in the U.S. is estimated at US$221.6 Million in the year 2020.
  • In the global Positron Emission Tomography segment, USA, Canada, Japan, China and Europe will drive the 2.3% CAGR estimated for this segment.

Worldwide Insights on the Positron Emission Tomography Scanners Industry to 2030

Retrieved on: 
Thursday, January 7, 2021
Nuclear medicine, Physical sciences, Medicine, Medical physics, Medical imaging, Neuroimaging, Antimatter, Medicinal radiochemistry, Positron emission tomography, Positron emission, Positron Corporation

Secondary research involves referring to key players' product literature, annual reports, press releases, and relevant documents to understand the global positron emission tomography (PET) scanners market.

Key Points: 
  • Secondary research involves referring to key players' product literature, annual reports, press releases, and relevant documents to understand the global positron emission tomography (PET) scanners market.
  • Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global positron emission tomography (PET) scanners market.
  • Furthermore, the report sheds light on changing competitive dynamics in the global positron emission tomography (PET) scanners market.
  • What will be the Y-o-Y growth of the global positron emission tomography (PET) scanners market between 2020 and 2030?

Global Positron Emission Tomography [PET] Scanners Market (2020 to 2030) - Industry Analysis, Size, Share, Growth, Trends and Forecast - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 5, 2021
Radiology, Health, Medical devices, Nuclear medicine, Medicine, Physics, Medical imaging, Medical physics, Neuroimaging, Antimatter, Medicinal radiochemistry, Positron emission tomography, PET-CT, Tomography, Positron Corporation

The "Positron Emission Tomography [PET] Scanners Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Positron Emission Tomography [PET] Scanners Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
  • The report also provides the compound annual growth rate (CAGR) for the global positron emission tomography (PET) scanners market during the forecast period.
  • What is the influence of changing trends in nuclear medicine and PET/CT on the global positron emission tomography (PET) scanners market?
  • Which factors are anticipated to impede the growth of the global positron emission tomography (PET) scanners market during the forecast period?

Global Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 15, 2020
Health, Pharmaceutical, Medicinal radiochemistry, Radiology, Nuclear medicine, Medicine, Medical physics, Medical imaging, Medical specialties, Radiation therapy, Positron Corporation

The "Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
  • The 'Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030' report provides a detailed study on the current market landscape and future potential of the companies having the capabilities to manufacture radiopharmaceuticals.
  • Who are the leading industry and non-industry players engaged in the nuclear medicine and radiopharmaceutical manufacturing market?
  • What are the key factors that are likely to influence the evolution of the nuclear medicine and radiopharmaceutical manufacturing market?

Positron launches Intellectual Property License Program for its VR Platform

Retrieved on: 
Sunday, September 20, 2020
Medical imaging, Positron Corporation, XR

The Positron IP Licensing program will make available the patents, designs and software suite of Positron's award-winning VR chair for partner companies to manufacture and sell their own customized VR chairs.

Key Points: 
  • The Positron IP Licensing program will make available the patents, designs and software suite of Positron's award-winning VR chair for partner companies to manufacture and sell their own customized VR chairs.
  • Brogent Global, Inc. signed a non-exclusive patent license agreement with Positron, becoming the first company to license the technology.
  • In addition to its Voyager hardware and software system, Positron also continues to license cinematic VR content titles in its capacity as a VR distributor.
  • At the Cannes XR festival this year, Positron introduced six finalists and a winner for the Positron Visionary Award, recognizing excellence in cinematic VR.

Preventice Solutions Receives Frost & Sullivan Global Remote Cardiac Monitoring Company of the Year Award

Retrieved on: 
Tuesday, September 1, 2020
Cardiac electrophysiology, Health software, Preventice, Cardiac monitoring, Branches of biology, Biology, Napier Healthcare, Positron Corporation

Award reflects excellence in visionary innovation, performance, and customer impact

Key Points: 
  • Award reflects excellence in visionary innovation, performance, and customer impact
    MINNEAPOLIS, Sept. 1, 2020 /PRNewswire/ --Preventice Solutions, a leader in digital healthcare solutions and remote cardiac monitoring services powered by deep learning and artificial intelligence (AI), announced today it received the 2020 Frost & Sullivan Global Remote Cardiac Monitoring Company of the Year Award.
  • "We are honored to be selected by Frost & Sullivan to receive this award for our commitment to delivering innovation and clinical value to patients and healthcare providers in the global remote cardiac monitoring market," said Jon P. Otterstatter, Chief Executive Officer of Preventice Solutions.
  • Frost & Sullivan justified its recognition of Preventice Solutions as the global Company of the Year recipient in the remote cardiac monitoring market due to the following factors:
    Preventice Solutions offers a comprehensive portfolio of highly accurate and sensitive BodyGuardian family of remote monitors.
  • Preventice Solutions is a leading developer of mobile health solutions and remote monitoring services that connect patients threatened by cardiac arrhythmias.

United Imaging Announces New Technology That Advances Molecular Imaging, Hints at a Series of New Announcements

Retrieved on: 
Saturday, July 11, 2020
Medical imaging, Medicine, Medical physics, Neuroimaging, Nuclear medicine, Image processing, Tomography, CT scan, Society of Nuclear Medicine and Molecular Imaging, Molecular imaging, Positron emission tomography, Positron Corporation

HOUSTON, July 11, 2020 /PRNewswire/ --United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, continues to set a new standard in molecular imaging and redefine nuclear medicine.

Key Points: 
  • HOUSTON, July 11, 2020 /PRNewswire/ --United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, continues to set a new standard in molecular imaging and redefine nuclear medicine.
  • United Imaging will host a virtual booth at the 2020 SNMMI Annual Meeting and will meet with customers in that environment and through its own virtual meeting technology.
  • For SNMMI, United Imaging announced that HYPER Iterative functionality is FDA cleared for its uMI 550 digital positron emission tomography (PET) / computed tomography (CT) scanner.
  • United Imaging also announced that more than 3,500 clinical patients have been scanned on its uEXPLORER total-body PET/CT system.

Intermountain Healthcare Partners with Care to Care, LLC to Manage Advanced Imaging Services

Retrieved on: 
Tuesday, July 7, 2020
Medicine, Medical physics, Image processing, Medical imaging, Nuclear medicine, Positron Corporation, Tomography, Positron emission tomography, American College of Cardiology, American College of Radiology

Working closely with Intermountain Healthcare providers and hospitals, Care to Care assists in promoting the safe use of advanced imaging and provides an objective basis for informed evidence-based clinical decisions.

Key Points: 
  • Working closely with Intermountain Healthcare providers and hospitals, Care to Care assists in promoting the safe use of advanced imaging and provides an objective basis for informed evidence-based clinical decisions.
  • "Care to Care is excited to collaborate with Intermountain Healthcare providers to promote the most effective use of advanced imaging studies through informed clinical decision-making that results in better patient outcomes.
  • Care to Care partnered with Intermountain Healthcare to manage outpatient advanced imaging for its members including; magnetic resonance (MR), computed tomography (CT), positron emission tomography (PET) and nuclear cardiology (NUC).
  • Together, Care to Care and Intermountain Healthcare are focused on promoting a culture of increasingly thoughtful and judicious use of medical imaging.